Fill and finish contract manufacturer Vetter announced Tuesday the production of the first commercial batches with single-use identification numbers for product in South Korea. Vetter now implements product serialization for secondary packaging for one of the world’s leading pharmaceutical companies, which follows last year’s introduction of a comprehensive serialization service, according to a news release.
Contract development and manufacturing organisation Recipharm has completed a complex serialization project for China for one of its customers. The project was undertaken for a top-ten pharmaceutical company and involved screening and selecting suppliers between February and June 2013 and placing orders in early July 2013. Fifty seven (57) serialized batches have already been supplied since February 2014, the company reported in a news release.
Recipharm reportedly employed new technology to ensure each individual box has its own 1-D bar code and unique serial number.
Interested in providing traceability for your pharmaceutical products? Don't miss Janice Kite, Traceability Director Healthcare for GS1 Global Office, Healthcare, who will be presenting at Pharmapack Europe 2015 GS1 Standards: Relevant to the global pharmaceutical supply chain?
PMP News Editor Daphne Allen asked Kite a few questions in advance of the event.
A symposium on serialization and track and trace at Pharmapack Europe will explore the current requirements and offer ideas to tackle implementation challenges.
Pharmaceutical companies continue to face “a persistent and increasing threat from counterfeits that has led authorities and major life science companies to work on a reliable track-and-trace system for drugs and medical devices with marketing authorization,” reports Jean-Luc Lasne, international business development & alliance director, Adents Pharma.
Clondalkin Pharma & Healthcare has installed equipment for serializing cartons at its Cherry Orchard facility in Dublin. The Atlantic Zeiser Digiline 300 will be used to support track-and-trace efforts for product movement as well as authentication.
Given the staggered deadlines for Unique Device Identification and a lengthy phase-in period for U.S.-market pharmaceutical item-level serialization, healthcare product manufacturers have time to address some of the challenges in implementation. Solutions providers that exhibited at Pack Expo International and Pharma Expo 2014 shared their approaches in handling data and the packages themselves in an effort to provide the tight control needed for dependable line performance.
Aesica Pharmaceuticals S.r.l, the Italian division of contract development and manufacturing organization Aesica, is launching an integrated serialization system from QAD for two pharmaceutical products for the Chinese market. The project at Aesica's site in Pianezza reportedly complied with new requirements from China’s Food and Drug Administration (CFDA) that cut the serialization implementation deadline to just three months from its original 12 month timeline, the CDMO reported in a press release.
As FDA works on developing standards for the interoperable exchange of tracing information for finished human prescription drugs, questions about packaging are already being raised. To prepare for implementation of the Drug Supply Chain Security Act, the agency held a public workshop in May during which it discussed with stakeholders the exchange of transaction information, transaction history, and transaction statements each time drugs are transferred.
As the U.S. representative for Tri-Star Technologies and CertiRx, Key International is offering their technologies for detecting counterfeit pharmaceuticals, medical devices, and more. Tri-Star Technologies provides a cold laser marking system that can mark individual tablets, capsules, soft gels, or other pharmaceutical products. The indelible mark reportedly does not adversely affect the product. Patients can then obtain information about the marked individual tablets or capsules by using the CertiRx app with a cell phone by taking a picture of the dosage form.
Global pharmaceutical contract developer and manufacturer Aesica reports that it has introduced serialization services and begun commercial production of two anti-allergy product lines for the Chinese market at its Pianezza site, Italy, for a global, multinational client. The implementation took under six months to complete, with the first production of serialization batches just commenced, the company reports.